Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 11/2004

01-09-2004 | Review Article

The Impact of Fragility Fracture on Health-Related Quality of Life

The Importance of Antifracture Therapy

Authors: Ted Xenodemetropoulos, Shawn Davison, George Ioannidis, Dr Jonathan D. Adachi

Published in: Drugs & Aging | Issue 11/2004

Login to get access

Abstract

Both general and specific health status instruments can be utilised in evaluating health-related quality of life (HR-QOL) deficits resulting from osteoporotic fractures. Osteoporotic hip, vertebral and wrist fractures significantly decrease HR-QOL in most HR-QOL domains investigated. The presence of multiple vertebral fractures leads to larger decrements in HR-QOL. More research needs to be completed with these HR-QOL tools to better assess the true burden of osteoporotic fractures, particularly in the case of hip fractures, as the burden is surely being underestimated without recognition of HR-QOL. Only when the burden of fragility fractures is understood, inclusive of HR-QOL, will the value of proven antifracture prevention and treatment therapies be appreciated. Information collected by HR-QOL instruments may provide new insight as to how to improve quality of life for patients with fractures and how to properly allocate healthcare spending.
Literature
1.
National Institutes of Health. Osteoporosis prevention diagnosis and therapy. NIH consensus statement. Natl Instit Health 2000; 17(1): 1–45
2.
Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103(2A): 3S–8SPubMedCrossRef
3.
Bengner U, Johnell O, Redlund-Johnell I. Increasing incidence of tibia condyle and patella fractures. Acta Orthop Scand 1986; 57(4): 334–6PubMedCrossRef
4.
Luthje P, Nurmi I, Kataja M, et al. Incidence of pelvic fractures in Finland in 1988. Acta Orthop Scand 1995; 66(3): 245–8PubMedCrossRef
5.
Rose SH, Melton III LJ, Morrey BF, et al. Epidemiologic features of humeral fractures. Clin Orthop 1982; 168: 24–30PubMed
6.
Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12(5): 417–27PubMedCrossRef
7.
Nguyen TV, Center JR, Sambrook PN, et al. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am J Epidemiol 2001; 153(6): 587–95PubMedCrossRef
8.
Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7(9): 1005–10PubMedCrossRef
9.
Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151(10): 2026–32PubMedCrossRef
10.
Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994; 15(4): 377–86PubMedCrossRef
11.
Kanis JA, Geusens P, Christiansen C. Guidelines for clinical trials in osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1991; 1(3): 182–8PubMedCrossRef
12.
Reginster JY, Compston JE, Jones EA, et al. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int 1995; 57(4): 247–50PubMedCrossRef
13.
Silverman SL, Cranney A. Quality of life measurement in osteoporosis. J Rheumatol 1997; 24(6): 1218–21PubMed
14.
Tosteson AN, Hammond CS. Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002; 20(5): 289–303PubMedCrossRef
15.
Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): Sl–34
16.
Hallworth RB. Prevention and treatment of postmenopausal osteoporosis. Pharm World Sci 1998; 20(5): 198–205PubMedCrossRef
17.
Hays RD, Hahn H, Marshall G. Use of the SF-36 and other health-related quality of life measures to assess persons with disabilities. Arch Phys Med Rehabil 2002; 83 (12 Suppl. 2): S4–9PubMedCrossRef
18.
Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002; 83 (12 Suppl. 2): S10–7PubMedCrossRef
19.
Tulsky DS, Rosenthal M. Measurement of quality of life in rehabilitation medicine: emerging issues. Arch Phys Med Rehabil 2003; 84 (4 Suppl. 2): Sl–2
20.
Guyatt GH, Naylor CD, Juniper E, et al. Users’ guides to the medical literature: XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA 1997; 277(15): 1232–7PubMedCrossRef
21.
Cook DJ, Guyatt GH, Adachi JD, et al. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int 1999; 10(3): 207–13PubMedCrossRef
22.
Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296(13): 716–21PubMedCrossRef
23.
Tosteson AN. Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine 1997; 22 (24 Suppl.): 58S–62SPubMedCrossRef
24.
Melton III LJ. Cost-effective treatment strategies for osteoporosis. Osteoporos Int 1999; 9Suppl. 2: S111–6PubMedCrossRef
25.
Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002; 13(10): 768–76PubMedCrossRef
26.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–83PubMedCrossRef
27.
Ware Jr JE, Kosinski M, Gandek B, et al. The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 1159–65PubMedCrossRef
28.
Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multi-centre Osteoporosis Study Research Group. CMAJ 2000; 163(3): 265–71PubMed
29.
Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with longstanding vertebral osteoporotic fracture. Osteoporos Int 1999; 9(6): 508–15PubMedCrossRef
30.
Randell AG, Nguyen TV, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000; 11(5): 460–6PubMedCrossRef
31.
Tosteson AN, Gabriel SE, Grove MR, et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12(12): 1042–9PubMedCrossRef
32.
Lombardi Jr I, Oliveira LM, Monteiro CR, et al. Evaluation of physical capacity and quality of life in osteoporotic women. Osteoporos Int 2004; 15(1): 80–5PubMedCrossRef
33.
Ethgen O, Tellier V, Sedrine WB, et al. Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? Bone 2003; 32(6): 718–24PubMedCrossRef
34.
Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1(1): 54PubMedCrossRef
35.
Boyle MH, Furlong W, Feeny D, et al. Reliability of the Health Utilities Index: Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 1995; 4(3): 249–57PubMedCrossRef
36.
Adachi JD, Ioannidis G, Pickard L, et al. The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2003; 14(11): 895–904PubMedCrossRef
37.
Gabriel SE, Kneeland TS, Melton III LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999; 19(2): 141–8PubMedCrossRef
38.
Tidermark J, Bergstrom G, Svensson O, et al. Responsiveness of the EuroQol (EQ 5-D) and the SF-36 in elderly patients with displaced femoral neck fractures. Qual Life Res 2003; 12(8): 1069–79PubMedCrossRef
39.
Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15(7): 1384–92PubMedCrossRef
40.
Cockerill W, Lunt M, Silman AJ, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004; 15(2): 113–9PubMedCrossRef
41.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33(5): 337–43PubMedCrossRef
42.
Lydick E, Zimmerman SI, Yawn B, et al. Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). J Bone Miner Res 1997; 12(3): 456–63PubMedCrossRef
43.
Chandler JM, Martin AR, Girman C, et al. Reliability of an osteoporosis-targeted quality of life survey instrument for use in the community: OPTQoL. Osteoporos Int 1998; 8(2): 127–35PubMedCrossRef
44.
Martin AR, Sornay-Rendu E, Chandler JM, et al. The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002; 31(1): 32–6PubMedCrossRef
45.
Lips P, Cooper C, Agnusdei D, et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 1999; 10(2): 150–60PubMedCrossRef
46.
Falch JA, Bentzen H, Dahl AA. Pain, functional level and emotional problems of women with osteoporosis and vertebral fractures [in Norwegian]. Tidsskr Nor Laegeforen 2004; 123(23): 3355–7
47.
Murrell P, Todd CJ, Martin A, et al. Postal administration compared with nurse-supported administration of the QUALEFFO-41 in a population sample: comparison of results and assessment of psychometric properties. Osteoporos Int 2001; 12(8): 672–9PubMedCrossRef
48.
Kocyigit H, Gulseren S, Erol A, et al. The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Clin Rheumatol 2003; 22(1): 18–23PubMedCrossRef
49.
Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group. Osteoporos Int 1997; 7(5): 478–87
50.
Badia X, Diez-Perez A, Alvarez-Sanz C, et al. Measuring quality of life in women with vertebral fractures due to osteoporosis: a comparison of the OQLQ and QUALEFFO. Qual Life Res 2001; 10(4): 307–17PubMedCrossRef
51.
Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 2003; 14(8): 677–82PubMedCrossRef
52.
Kessenich CR, Guyatt GH, Rosen CJ. Health-related quality of life and participation in osteoporosis clinical trials. Calcif Tissue Int 1998; 62(3): 189–92PubMedCrossRef
53.
Ioannidis G, Gordon M, Adachi JD. Quality of life in osteoporosis. Nurs Clin North Am 2001; 36(3): 481–9PubMed
54.
Adachi JD, Ioannidis G, Olszynski, et al. The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002; 3(1): 11PubMedCrossRef
55.
Randell AG, Bhalerao N, Nguyen TV, et al. Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. J Rheumatol 1998; 25(6): 1171–9PubMed
56.
Oglesby AK, Minshall ME, Shen W, et al. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol 2003; 30(7): 1579–83PubMed
57.
Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001; 44(11): 2611–9PubMedCrossRef
58.
Helmes E, Hodsman A, Lazowski D, et al. A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. J Gerontol A Biol Sci Med Sci 1995; 50(2): M91–8PubMedCrossRef
59.
Marquis P, Cialdella P, De la LC. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 2001; 10(6): 555–66PubMedCrossRef
60.
Greendale GA, Barrett-Connor E, Ingles S, et al. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 1995; 43(9): 955–61PubMed
61.
Adachi JD, Ioannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001; 12(11): 903–8PubMedCrossRef
62.
Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320(7231): 341–6PubMedCrossRef
63.
Cummings SR, Phillips SL, Wheat ME, et al. Recovery of function after hip fracture: the role of social supports. J Am Geriatr Soc 1988; 36(9): 801–6PubMed
64.
Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990; 45(3): M101–7PubMedCrossRef
65.
Marottoli RA, Berkman LF, Cooney Jr LM. Decline in physical function following hip fracture. J Am Geriatr Soc 1992; 40(9): 861–6PubMed
66.
Koot VC, Peeters PH, de Jong JR, et al. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg 2000; 166(6): 480–5PubMedCrossRef
67.
Papaioannou A, Watts NB, Kendler DL, et al. Diagnosis and management of vertebral fractures in elderly adults. Am J Med 2002; 113(3): 220–8PubMedCrossRef
68.
Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 1993; 36(6): 750–6PubMedCrossRef
69.
Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996; 156(21): 2469–75PubMedCrossRef
70.
Burger H, Van Daele PL, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997; 12(1): 152–7PubMedCrossRef
71.
72.
Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996; 18 (3 Suppl.): 185S–9SPubMedCrossRef
73.
Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128(10): 793–800PubMed
74.
Begerow B, Pfeifer M, Pospeschill M, et al. Time since vertebral fracture: an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 1999; 10(1): 26–33PubMedCrossRef
75.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–41PubMedCrossRef
76.
Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1992; 7(2): 221–7PubMedCrossRef
77.
Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160(1): 77–85PubMedCrossRef
78.
Altissimi M, Antenucci R, Fiacca C, et al. Long-term results of conservative treatment of fractures of the distal radius. Clin Orthop 1986; 206: 202–10PubMed
79.
Field J, Warwick D, Bannister GC, et al. Long-term prognosis of displaced Colles’ fracture: a 10-year prospective review. Injury 1992; 23(8): 529–32PubMedCrossRef
80.
Warwick D, Field J, Prothero D, et al. Function ten years after Colles’ fracture. Clin Orthop 1993; 295: 270–4PubMed
81.
de Bruijn HP. Functional treatment of Colles fracture. Acta Orthop Scand Suppl 1987; 223: 1–95PubMed
82.
Kaukonen JP, Karaharju EO, Porras M, et al. Functional recovery after fractures of the distal forearm: analysis of radiographic and other factors affecting the outcome. Ann Chir Gynaecol 1988; 77(1): 27–31PubMed
83.
Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles’ fracture patients. Osteoporos Int 1999; 9(3): 196–9PubMedCrossRef
84.
Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285(3): 320–3PubMedCrossRef
85.
Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25(1): 97–106PubMedCrossRef
86.
Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95(6): 557–67PubMedCrossRef
87.
Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322(18): 1265–71PubMedCrossRef
88.
Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323(2): 73–9PubMedCrossRef
89.
van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998; 37(1): 87–94PubMedCrossRef
90.
Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997; 103(6): 468–76PubMedCrossRef
91.
Burger H, Herings RM, Egberts AC, et al. Cyclical etidronate use is not associated with symptoms of peptic ulcer disease. Eur J Clin Pharmacol 2000; 56(4): 319–22PubMedCrossRef
92.
van Staa TP, Leufkens H, Abenhaim L, et al. Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy 1998; 18(5): 1121–8PubMed
93.
Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002; 25(11): 781–90PubMedCrossRef
94.
Chesnut III CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99(2): 144–52PubMedCrossRef
95.
Devogelaer JP, Broil H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18(2): 141–50PubMedCrossRef
96.
Liberman UA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333(22): 1437–43PubMedCrossRef
97.
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): 2077–82PubMedCrossRef
98.
Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85(11): 4118–24PubMedCrossRef
99.
Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9(5): 461–8PubMedCrossRef
100.
McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128(4): 253–61PubMed
101.
Levis S, Quandt SA, Thompson D, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002; 50(3): 409–15PubMedCrossRef
102.
Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 2001; 12(8): 654–60PubMedCrossRef
103.
104.
Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160(4): 517–25PubMedCrossRef
105.
Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12(1): 1–12
106.
Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77(10): 1044–52PubMedCrossRef
107.
Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97(1): 58–64PubMedCrossRef
108.
Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4(10): 1377–82PubMed
109.
Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162(8): 936–42PubMedCrossRef
110.
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333–40PubMedCrossRef
111.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344–52PubMedCrossRef
112.
Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11(1): 83–91PubMedCrossRef
113.
Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32(2): 120–6PubMedCrossRef
114.
Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001; 68(11): 945–51PubMedCrossRef
115.
Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119(3): 631–8PubMedCrossRef
116.
Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29(9): 1965–74PubMed
117.
Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95(11): 3112–7PubMedCrossRef
118.
Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77(3): 262–70PubMedCrossRef
119.
Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001; 13(5): 347–54
120.
Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109(4): 267–76PubMedCrossRef
121.
Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98(5): 452–8PubMedCrossRef
122.
Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24(8): 565–9PubMedCrossRef
123.
Ellerington MC, Hillard TC, Whitcroft SI, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59(1): 6–11PubMedCrossRef
124.
Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305(6853): 556–61PubMedCrossRef
125.
Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15(4): 284–9PubMedCrossRef
126.
Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures: a double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997; 275: 112–4PubMed
127.
Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11(2): 205–9PubMed
128.
129.
Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998; 83(7): 2239–43PubMedCrossRef
130.
Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339(11): 733–8PubMedCrossRef
131.
Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis: V. meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23(4): 529–39PubMedCrossRef
132.
Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001; 2(1): 7PubMedCrossRef
133.
Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285(22): 2891–7PubMedCrossRef
134.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33PubMedCrossRef
135.
Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285(22): 2891–7PubMedCrossRef
136.
Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168 (3 Pt 1): 824–30PubMed
137.
Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003; 44(2): 157–63PubMedCrossRef
138.
Tosteson AN, Gabriel SE, Kneeland TS, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000; 9(2): 119–30PubMedCrossRef
139.
Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348(19): 1839–54PubMedCrossRef
140.
Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94(25): 14105–10PubMedCrossRef
141.
Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10(4): 337–44PubMedCrossRef
142.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): 637–45PubMedCrossRef
143.
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–7PubMedCrossRef
144.
Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162(10): 1140–3PubMedCrossRef
145.
Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87(8): 3609–17PubMedCrossRef
146.
Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int 2002; 13(11): 907–13PubMedCrossRef
147.
Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65(2): 125–34PubMedCrossRef
148.
Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7): 847–57PubMedCrossRef
149.
Barrett-Connor E, Ensrud KE, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25(3): 919–30PubMedCrossRef
150.
Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93(4): 558–65PubMedCrossRef
Metadata
Title
The Impact of Fragility Fracture on Health-Related Quality of Life
The Importance of Antifracture Therapy
Authors
Ted Xenodemetropoulos
Shawn Davison
George Ioannidis
Dr Jonathan D. Adachi
Publication date
01-09-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421110-00002

Other articles of this Issue 11/2004

Drugs & Aging 11/2004 Go to the issue

Review Article

The Application of Fuzzy Logic to the Prescription of Antithrombotic Agents in the Elderly

Original Research Article

Induction Immunosuppression in Kidney Transplant Recipients Older than 60 Years of Age

Review Article

Subcutaneous Apomorphine

Original Research Article

Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits